News for Puma Biotechnology, Inc. (PBYI)

Company positions for long-term growth in medical device markets Salt Lake City, UT, April 03, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. ( SINT), an

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2025, the Compensation Committee of Puma's Board of Directors

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Total Revenue: $59.1 million for Q4 2024.Product Revenue Net: $54.4 million for Q4 2024.Royalty Revenue: $4.7 million for Q4 2024.Net Income (GAAP): $19.3 mill

Feb 27, 2025 / 09:30PM GMTOperator Good afternoon. My name is Darryl, and I will be your conference call operator today. (Operator Instructions) As a reminder,

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsMariann Ohanesian – Senior...

The following slide deck was published by Puma Biotechnology, Inc.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder

Puma Biotechnology CFO sells shares worth $32,232

Puma Biotechnology chief commercial officer sells $29,742 in stock

Puma Biotechnology's SVP sells $27,208 in stock

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma's Board of Director

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Sales of PBYI's sole-marketed drug, Nerlynx exceeded management's expectations in the third quarter. Also, the acquisition of alisertib holds promise.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guideli

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 2, 2024, the Compensation Committee of Puma's Board of Directo

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCAâ„¢-Breast1) Phase II trial (P